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Background: Immunoglobulin treatment modulates immune function by enhancing the natural antibody repertoire or by down-regulating 
T cell function. We investigated serum-derived, non-immune polyclonal IgM (Poly-IgM) as treatment for atherosclerosis in mice with advanced 
atherosclerotic disease and assessed its immune-modulatory effects. 
Methods and Results: Aortic atherosclerosis was assessed in apoE-/- mice, fed atherogenic diet starting at 6 weeks of age. The mice were also 
subjected to carotid cuff injury at 25 weeks of age as a model of accelerated atherosclerosis. At the time of injury, the mice were treated weekly with 
a commercially available Poly-IgM (0.4 mg/mouse) or PBS for 4 weeks and euthanized at 29 weeks of age. Poly-IgM reduced aortic atherosclerosis 
and lesion size in the injured carotid artery (Table), without changes in serum cholesterol levels. The immune-modulatory effect of Poly-IgM treatment 
was observed with increased oxLDL IgG titers compared with PBS (Table). Percentage of splenic CD4+ T cells was reduced in the Poly-IgM group. 
Splenocytes cultured from the Poly-IgM treated mice had reduced CD4+ T cell proliferation in vitro compared with splenocytes from PBS group. 
Conclusion: Treatment with Poly-IgM reduced atherosclerosis in apoE-/- mice through enhanced oxLDL IgG titers and downward modulation 
of number and proliferative function of CD4+ T cells. The study identifies a novel role for non-immune polyclonal IgM in reducing atherosclerosis 
through immune-modulation. 
% Aorta
En-face
Carotid artery
Intimal area*
oxLDL IgG‡
% CD4+
Spleen cells 
% Proliferating CD4+ 
Cells (in vitro)
PBS
21.0+5.4
(n=12)
3.4+2.5
(n=12)
0.14+0.06
(n=10)
23.8+7.5
(n=11)
24.2+0.6
(n=4)
Poly-IgM
15.9+6.4†
(n=15)
1.5+1.0†
(n=12)
0.32+0.31†
(n=15)
11.3+6.3†
(n=10)
13.0+1.9†
(n=3)
*Area x 10-2 mm sq. †p<0.05; ‡IgG values expressed as OD 405.
